Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.45 |
| ▸ | HTR2A | P28223 | 15/20 | 0.45 |
| ▸ | DRD3 | P35462 | 15/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6296077 | 0.95 | DRD2 (0.47) | DRD2HTR2ADRD3SLC6A4HTR1A | |
| SCHEMBL6296072 | 0.82 | DRD2 (0.41) | DRD2HTR2ADRD3SLC6A4 | |
| SCHEMBL5345674 | 0.79 | DRD2 (0.51) | DRD2SLC6A4 | |
| SCHEMBL6296111 | 0.78 | DRD2 (0.43) | DRD2HTR2ADRD3SLC6A4HTR1A | |
| SCHEMBL6214213 | 0.78 | DRD2 (0.50) | DRD2HTR2ADRD3SLC6A4HTR1A | |
| SCHEMBL5335268 | 0.77 | DRD2 (0.52) | DRD2HTR2ADRD3SLC6A4HTR1A | |
| SCHEMBL5569217 | 0.77 | SLC6A4 (0.48) | DRD2HTR2ADRD3SLC6A4HTR1A | |
| SCHEMBL5332520 | 0.75 | DRD2 (0.53) | DRD2HTR2ADRD3SLC6A4HTR1A | |
| SCHEMBL5334230 | 0.74 | DRD2 (0.52) | DRD2HTR2ADRD3SLC6A4HTR1A | |
| SCHEMBL6215166 | 0.72 | MAOB (0.53) | DRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908922-B2 | Anticholesterol agents; cardiovascular disorders | LES LABORATOIRES SERVIER (FR) | 2005-06-21 | — | — | US | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | DRD2 3536/4885HTR2A 2477/4885DRD3 2304/4885 |
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | DRD2 3284/4885HTR2A 2171/4885DRD3 2124/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | DRD2 3284/4885HTR2A 2171/4885DRD3 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.